ɬÀï·¬

Building the blueprint to block HIV

Wesley Sundquist will present his work on the HIV capsid and revolutionary drug, Lenacapavir, at the ASBMB Annual Meeting, March 7–10, in Maryland.

Gut microbes hijack cancer pathway in high-fat diets

Researchers at the Feinstein Institutes for Medical Research found that a high-fat diet increases ammonia-producing bacteria in the gut microbiome of mice, which in turn disrupts TGF-β signaling and promotes colorectal cancer.

Sex and diet shape fat tissue lipid profiles in obesity

Researchers found that sex hormone levels and diet both influence inflammation and lipid composition in obesity.

Training AI to uncover novel antimicrobials

Antibiotic resistance kills millions, but César de la Fuente’s lab is fighting back. By pairing AI with human insight, researchers are uncovering hidden antimicrobial peptides across the tree of life with a 93% success rate against deadly pathogens.

AI-designed biomarker improves malaria diagnostics

Researchers from the University of Melbourne engineered Plasmodium vivax diagnostic protein with enhanced yield and stability while preserving antibody-binding, paving the way for more reliable malaria testing.

Antibiotic sensor directly binds drug in resistant bacteria

Researchers at Drexel University uncover how the vancomycin-resistant bacterial sensor binds to the antibiotic, offering insights to guide inhibitor design that restores antibiotic effectiveness against hospital-acquired infections.

How HCMV hijacks host cells — and beyond

Ileana Cristea, an ASBMB Breakthroughs webinar speaker, presented her research on how viruses reprogram cell structure and metabolism to enhance infection and how these mechanisms might link viral infections to cancer and other diseases.

Engineered fusion protein targets kiwifruit pathogen

Synthetic protein selectively kills kiwifruit pathogen, offering a promising biocontrol strategy for agriculture. Read more about this recent JBC paper.

Pathogen-derived enzyme engineered for antibiotic design

Engineered variants of a bacterial enzyme developed at the University at Buffalo accept larger substrates, paving the way for new acinetobactin-based antimicrobials. Read more about this recent JBC paper.